NEW YORK (GenomeWeb News) – Vermillion today announced a definitive agreement with Pronto Diagnostics to serve as the exclusive distributor of the OVA1 ovarian cancer test in Israel and the Palestinian territories.
Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.
Financial and other terms of the agreement were not released.
In a statement, Gail Page, president and CEO of Vermillion, said that Israel and the Palestinian territories represent a market opportunity of about 6 million women, and the deal with Pronto "further supports our expansion efforts as we continue to develop our international strategy in concert with the efforts already underway in the US."
Based in Israel, Pronto offers a clinical laboratory, regulatory expertise, a broad distribution network, and experience distributing oncology products in its geography, Vermillion said.